Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Divis to spend Rs 300...

    Divis to spend Rs 300 crore on expansion plans in 2018

    Written by Ruby Khatun Khatun Published On 2018-01-31T10:45:46+05:30  |  Updated On 31 Jan 2018 10:45 AM IST
    Divis to spend Rs 300 crore on expansion plans in 2018

    HYDERABAD: Drug firm Divis Laboratories is focussed on expanding capacities of existing plants, even as its proposed plant at Kakinada, Andhra Pradesh ran into rough weather, a senior official of the city-based drug maker said here.


    The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during the current year, L Kishore Babu chief financial officer said.


    "Kakinada plant (in AP) may take some more time. The state government has to resolve the farmer's issue. We will not undertake any work there until the farmer's issue is resolved. So we are expanding the capacities of the existing plants," Kishore Babu told PTI here.


    "Capex for next year has not yet been decided. By March we will finalize it," he added.


    The state government allotted 505 acres of land at Ontimamidi Village (Kona), Thondangi Mandal, East Godavari District, and gave the company advance possession of the land, pending procedural formalities.


    The company has spent an amount of Rs 34.35 crore last year towards the cost of land and minor civil works at the site. The government has registered land of an extent of 351.72 acres in favour of the company, Divis said in its annual report of FY17.


    Several farmers whose land had been acquired or resumed by the government moved the High Court either contesting the acquisition or seeking higher compensation.


    Replying to a query, Kishore Babu said production at their Visakhapatnam plant has been normalized after the USFDA gave establishment inspection report (EIR) to the facility.


    "Production in the Vizag plant has been normalized," he added.


    Divis which has four manufacturing facilities is engaged in manufacturing leading generic compounds, nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies, the annual report said.

    Andhra PradeshDivi'sDivis LaboratoriesDivis LabsEIREstablishment Inspection ReportExpansionL Kishore Babupharma newsUSFDAVisakhapatnam plantVizag plant
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok